Adhesions cause small bowel obstruction (leading to cramps and nausea), female infertility (in up to 30%), chronic pain and prolonged and complicated repeat surgeries (35% of patients within 10 years). Following abdominopelvic surgery, almost 80% of patients develop some level of adhesions between organs and/or the abdominal wall. These adhesions are caused by inflammatory processes and inappropriate healing.
Current barrier products fail to tap most of the market potential with only 260.000 patients being treated per year in the EU while about 7 million patients in gynecology and general surgery in the EU and US are at risk of developing post-surgical adhesions. Western world market size is estimated to be €300 million, with great upward potential. There is a clear demand for effective and safe treatment options in order to achieve patient safety and prevent additional costs for healthcare systems.
HydroGlaze is an easy-to-use, efficacious and safe sprayable adhesion barrier device suitable for laparoscopic and open surgeries. The hydrogel builds a mechanical layer between tissues and thereby prevents adhesion formation. The components include colour that indicate areas already sprayed upon by the surgeon. Clinical testing shows efficacy, safety and user-friendliness of HydroGlaze.
CE marking has been approved and European market entry is planned for 2021. Production facilities are currently located in the US and may be moved to Europe. Market entry for the US is planned for 2024, based on currently planned trials.
Meet the team
Taco van der Feltz
NLC Venture Partner
A highly international and networked entrepreneur trained as Medical Doctor and Medical Biologist, he is a visionary strategist conversant within and across disciplines. As Venture Partner, his focus is on building innovative companies and strengthening NLC’s abilities to bring innovations to healthcare.